Please check your internet connection and try again.
```markdown
# Mylotarg (gemtuzumab ozogamicin)
## Overview
Mylotarg is a humanized monoclonal antibody conjugated to a cytotoxic agent, ozogamicin. It targets the CD33 antigen, which is expressed on the surface of myeloid leukemia cells.
## Primary Indications
* Acute Myeloid Leukemia (AML) in adults who are newly diagnosed and unfit for intensive induction chemotherapy.
* AML in adults who have relapsed or are refractory to treatment.
## Adult Dosing
* **Newly Diagnosed AML (unfit for intensive induction):**
* A single dose of **6 mg/m²** administered intravenously on Day 1.
* A second dose of **3 mg/m²** administered intravenously on Day 4.
* A third dose of **3 mg/m²** administered intravenously on Day 7.
* **Relapsed or Refractory AML:**
* A single dose of **6 mg/m²** administered intravenously on Day 1.
* A second dose of **3 mg/m²** administered intravenously on Day 4.
* A third dose of **3 mg/m²** administered intravenously on Day 7.
* Maximum cumulative dose should not exceed **70 mg/m²**.
## Pediatric Dosing
Data on pediatric use is limited. Dosing may be based on adult recommendations or specific institutional protocols. Consult pediatric oncology guidelines.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. If bilirubin > 1.6 mg/dL or AST/ALT > 3 times the upper limit of normal, consider delaying or reducing dose. Specific adjustment recommendations are not well-established and depend on clinical judgment and local protocols.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established. Monitor renal function closely.
## Contraindications
* None listed for the drug itself, but use is contraindicated in patients with severe hypersensitivity to gemtuzumab ozogamicin or any component of the formulation.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, mucositis, constipation, pyrexia, headache, rash, cough, fatigue, abdominal pain, decreased appetite, chills, muscle pain, insomnia, edema.
* **Serious:** Hepatotoxicity (including VOD/SOS), myelosuppression (including neutropenia, thrombocytopenia, anemia), hypersensitivity reactions, infusion-related reactions, tumor lysis syndrome, bleeding events.
## Key Drug Interactions
* **Hepatotoxic Agents:** Concurrent use with other drugs known to cause liver injury may increase the risk of hepatotoxicity.
* **Myelosuppressive Agents:** Concomitant use with other myelosuppressive chemotherapy may potentiate myelosuppression.
## Monitoring
* **Hepatotoxicity:** Monitor liver function tests (bilirubin, AST, ALT, alkaline phosphatase) regularly, especially before and during treatment. Promptly assess and manage signs and symptoms of VOD/SOS.
* **Myelosuppression:** Monitor complete blood counts (CBC) with differential and platelet counts frequently throughout treatment.
* **Infusion-related reactions and Hypersensitivity:** Monitor patients closely during and after infusion.
* **Bleeding Events:** Monitor for signs and symptoms of bleeding.
* **Tumor Lysis Syndrome:** Monitor electrolytes and renal function, especially in patients with a high tumor burden.
## Clinical Pearls
* Mylotarg carries a **Black Box Warning** for hepatotoxicity, including VOD/SOS, and for myelosuppression.
* VOD/SOS can occur during treatment or after discontinuation. Early recognition and management are crucial.
* Consider the potential for severe myelosuppression and the need for appropriate supportive care (e.g., growth factors, transfusions).
* Due to the risk of bleeding, use with caution in patients with active bleeding or those receiving anticoagulants.
* This drug is typically administered in an inpatient setting with close monitoring.
***
**Disclaimer:** This information is intended for clinical use and does not replace comprehensive drug information resources. Always consult the most current prescribing information and institutional protocols for complete details and to verify dosage and safety information before administering any medication.
```
